https://charts.traderzeitung.de/phases/US44486Q1031
string(1428) "{"isin":"US44486Q1031","name":"Humacyte Inc","stock_id_xnas":22560573,"stock_id_xnys":null,"generated_at":"2026-08-21 10:15:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.58,"close_at":"2026-08-18 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":0.6,"close_at":"2026-08-19 14:01:00","complete":true,"perf_pct":3.4483},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.739,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":23.1667},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":0.741,"close_at":"2026-08-20 00:28:00","complete":true,"perf_pct":0.2706}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.679,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-8.3671},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Humacyte Aktie News & Nachrichten
Trading-Room

Humacyte Aktie News & Nachrichten

[WKN: A3CZBW | Symbol: HUMA]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Humacyte

Humacyte Inc. (HUMA): H.C. Wainwright sieht nach der FDA-Zulassung 198 % Kurspotenzial!

Humacyte Inc. (HUMA) entwickelt eine biotechnologische Plattform, um universell implantierbare, bioengineerte...

  • ‹
  • 1
  • ›
Humacyte Nachrichtenticker öffnen
MT Newswires 27.07.2026 14:55 Uhr

Humacyte teilt mit, dass die US-amerikanische FDA den IND-Antrag für eine klinische Studie mit künstlich hergestellten Koronargefäßen am Menschen genehmigt hat

08:54 AM EDT, 27.07.2026 (MT Newswires) -- Humacyte (HUMA) teilte am Montag mit, dass die US-amerikanische Lebensmittel- und Arzneimittelbehörde (FDA)

MT Newswires 10.06.2026 22:52 Uhr

Humacyte sagt, ATEV erreichte Endpunkt einer Spätphasenstudie in Zwischenanalyse, startet öffentliches Angebot; Aktien fallen

04:51 PM EDT, 06/10/2026 (MT Newswires) -- Humacyte (HUMA) sagte am Mittwoch, dass sein biotechnologisch hergestelltes Blutgefäß, das azelluläre geweb